2021 Neuro-oncology Reading List, Learning Objectives, and CME

Reading List

Please click below to access the 2021 Neuro-oncology reading list.

C-cert Activity Description

The Continuous Certification (C-cert) activities provide subspecialty learning and knowledge assessment to ensure that diplomates are staying up to date on the latest science, treatments, and therapeutics relating to their subspecialty. The annual activities include: 1) reading the subspecialty  journal articles, and 2) taking and passing the 25-question online post-reading quiz to assess knowledge gained from the journal article content. 

Learning Objectives

• Correctly apply WHO 2016 classification criteria for diagnosis of diffuse gliomas and recommend appropriate therapy for newly diagnosed glioma patients based on these updated criteria
• Identify and avoid biases that lead to differential outcomes in glioblastoma patient survival based on racial and socioeconomic factors
• Appropriately prescribe prophylactic anticonvulsants and steroids for patients with brain metastases

Core Competencies

• Medical Knowledge

Continuing Medical Education (CME) Instructions

To claim CME credits, answer question 26 on the quiz to reflect the total time spent completing the required reading and online quiz. This question is not included in the scoring of the quiz. A passing score of 80% of higher is needed to meet C-cert requirements and receive CME credit. CME credit confirmation will be emailed within three weeks of passing the quiz.

ACCME Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Academy of Neurology Institute (AANI) and United Council for Neurologic Subspecialties. The AANI is accredited by the ACCME to provide continuing medical education for physicians.

AMA Credit Designation Statement

The American Academy of Neurology Institute designates this enduring material for a maximum of 11 AMA PRA Category 1^TM credit(s). Physicians should claim only their credit commensurate with the extent of the participation in the activity.

ABPN Self-Assessment Designation Statement

The American Board of Psychiatry & Neurology (ABPN) has reviewed the UCNS Continuous Certification (C-cert) self-assessment activity and has approved the program as a part of a comprehensive self-assessment (SA) program, which is mandates by the American Board of Medical Specialties as a necessary component of maintenance of certification. The number of ABPN SA credits granted will equal the number of CME hours claimed for the activity. 

Disclosures

The UCNS complies with all standards and policies of the ACCME, including identification and resolution of all conflicts of interest prior to the educational activity being delivered to learners. Accordingly, UCNS  planners, authors, and staff comply with the UCNS’s Conflicts of Interest Policy. 

2021 C-cert Activity Planner Disclosures
All relevant financial relationships have been mitigated.

Neuro-oncology Certification Examination Committee Contributors

Howard Colman, MD, PhD, Chair, University of Utah Huntsman Cancer Institute 
Disclosures: Serves on Advisory Board/Consultant for Best Doctors, Karyopharm Therapeutics, Private Health, Orbus, Bayer, and Forma Therapeutics. Receives research Funding (Site PI/Institutional Contract) from Newlink Genetics, Plexxikon, Kadmon, Orbus, Merck, DNATrix, Abbvie, Beigene, Forma Therapeutics, GCAR, and Array BioPharma. Receives research funding and research-related salary support from National Institutes of Health/National Cancer Institute, Alliance NCORP Research Base, NIH/NINDS, Huntsman Cancer Institute, and Jon M. Huntsman Presidential Endowed Chair.

Minesh P. Mehta, MD, Vice Chair, Baptist Health South Florida – Miami Cancer Institute
Disclosures: Is a consultant with Karyopharm and serves as member of the Board of Directors for Tocagen; Board of Directors: Oncoceutics; Received Oncoceutics 0.1% stock-option investment as a member of the Board of Directors.

Joy E. Burke, MD, University of Rochester
Disclosures: Receives compensation for consulting with Allergan regarding a migraine product. 

David M. Cachia, MD, Medical University of South Carolina
Disclosures: Nothing to disclose.

Christian Grommes, MD, Memorial Sloan Kettering Cancer Center
Disclosures: Receives consultation fees from BTG and Ono.

Yasmine Khakoo, MD, Memorial Sloan Kettering Cancer Center
Disclosures: Nothing to disclose.

Heather E. Leeper, MD, National Institute of Health
Disclosures: Nothing to disclose.

Douglas E. Ney, MD, University of Colorado – Anschutz Medical Campus
Disclosures: Receives compensation to serve on DNAtrix Therapeutics - Data Safety Monitoring Board. Receives research support from Orbus Therapeutics for role as Primary Investigator of national multi-site clinical trial and from Genentech for role as Primary Investigator of national multi-site clinical trial.

Katherine B. Peters, MD, PhD, Duke University Medical Center
Disclosures: Receives compensation for Advisory Boards-Agios, Boehringer, Bayer Research Grant-Abbvie, Agios, Biomimetix, Novocure; Received Research Grants-Abbvie, Agios, Biomimetix, Novocure.

Roy E. Strowd, III, MD, MEd, Wake Forest School of Medicine
Disclosures: Has commercial relationships with Monteris Medical, Novocure Inc, and Lecturio. Receives research support from American Society of Clinical Oncology, JAZZ Pharmaceuticals, and Southeastern Brain Tumor Foundation.

Staff Contact

Bryan Hagerla, Continuous Certification Manager
Disclosures: Nothing to disclose.
[email protected]
(612) 928-6326